Drug-Induced Leukopenia after Kidney Transplantation: Insights from Literature and a Clinical Case

Introduction: Leukopenia, particularly neutropenia, is a frequent hematological complication in kidney transplant recipients. It is most often related to immunosuppressive and prophylactic agents. These drugs are essential for preventing graft rejection and infection. However, they may induce myelosuppression. This leads to increased infection risk and often requires therapy modification. Materials and Methods: We conducted a narrative review of the literature by searching PubMed, Embase, and Scopus for studies published between January 2010 and June 2024. Search terms included “leukopenia,” “neutropenia,” “drug-induced,” “kidney transplantation,” “mycophenolate,” “valganciclovir,” “tacrolimus,” “cotrimoxazole,” and “myelosuppression.” Eligible studies involved adult kidney transplant recipients and reported drug-induced leukopenia. Results: Eight key studies were identified. Mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole were the most frequent causative agents. Tacrolimus was occasionally implicated. Reported incidence of leukopenia ranged from 19% to 83% during the first post-transplant year. Neutropenia occurred in up to 48% of patients. Risk factors included CMV D+/R− serostatus, combination therapy, and higher drug dosages. To illustrate clinical complexity, we present a case of a 36-year-old renal transplant recipient. He developed severe leukopenia and neutropenia two months post-transplant. White blood cell counts normalized following therapy adjustment and G-CSF administration, without subsequent rejection or infection. Conclusion: Drug-induced leukopenia is a common complication after kidney transplantation. It is seen particularly with mycophenolate and valganciclovir, and less often with tacrolimus. Early detection, individualized dose adjustment, and supportive therapies are essential. These measures balance infection prevention with adequate immunosuppression. Standardized management guidelines are lacking, highlighting the need for prospective studies.

Authors

Institutions

Publication Details

Journal
Albanian Journal of Trauma and Emergency Surgery
Published
2026-01-20
DOI
https://doi.org/10.32391/ajtes.v10i1.497
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Drug-Induced Leukopenia after Kidney Transplantation: Insights from Literature and a Clinical Case

Elvana Rista, Erjola Likaj, Armanda Saraci, Klejda Çollaku et al.
Albanian Journal of Trauma and Emergency Surgery
Blood disorders and treatments
article

Drug-Induced Leukopenia after Kidney Transplantation: Insights from Literature and a Clinical Case

Elvana Rista, Erjola Likaj, Armanda Saraci, Klejda Çollaku, Arjana Strakosha, Alma Idrizi
article en

Abstract

Introduction: Leukopenia, particularly neutropenia, is a frequent hematological complication in kidney transplant recipients. It is most often related to immunosuppressive and prophylactic agents. These drugs are essential for preventing graft rejection and infection. However, they may induce myelosuppression. This leads to increased infection risk and often requires therapy modification. Materials and Methods: We conducted a narrative review of the literature by searching PubMed, Embase, and Scopus for studies published between January 2010 and June 2024. Search terms included “leukopenia,” “neutropenia,” “drug-induced,” “kidney transplantation,” “mycophenolate,” “valganciclovir,” “tacrolimus,” “cotrimoxazole,” and “myelosuppression.” Eligible studies involved adult kidney transplant recipients and reported drug-induced leukopenia. Results: Eight key studies were identified. Mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole were the most frequent causative agents. Tacrolimus was occasionally implicated. Reported incidence of leukopenia ranged from 19% to 83% during the first post-transplant year. Neutropenia occurred in up to 48% of patients. Risk factors included CMV D+/R− serostatus, combination therapy, and higher drug dosages. To illustrate clinical complexity, we present a case of a 36-year-old renal transplant recipient. He developed severe leukopenia and neutropenia two months post-transplant. White blood cell counts normalized following therapy adjustment and G-CSF administration, without subsequent rejection or infection. Conclusion: Drug-induced leukopenia is a common complication after kidney transplantation. It is seen particularly with mycophenolate and valganciclovir, and less often with tacrolimus. Early detection, individualized dose adjustment, and supportive therapies are essential. These measures balance infection prevention with adequate immunosuppression. Standardized management guidelines are lacking, highlighting the need for prospective studies.

Albanian Journal of Trauma and Emergency SurgeryVol. 10(1)
Mother Teresa Hospital (AL), Hôpital régional (CH), Hygeia Hospital (GR), Uji Hospital (JP)
Good health and well-being
Openalex Percentile: Top 84%
Blood disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.